
    
      This study is planned to provide information on how the body processes epratuzumab and how
      epratuzumab affects the body when epratuzumab is given once weekly for 4 weeks in a row at
      one of 2 different dose levels. Additional information will be obtained related to the
      natural variability of disease activity in SLE patients.
    
  